

1 **Title:** Public perceptions of Ebola vaccines and confidence in health services to treat Ebola,
2 malaria, and tuberculosis: Findings from a cross-sectional household survey in Uganda, 2020

3
4 **Authors**

5 Aybüke Koyuncu¹, Rosalind J. Carter², Joseph Musaaazi³, Apophia Namageyo-Funa¹, Victoria M.
6 Carter¹, Mohammed Lamorde³, Dimitri Prybylski¹, Rose Apondi¹, Tabley Bakyaaita⁴, Amy L.
7 Boore¹, Jaco Homsy^{1,5}, Vance R. Brown¹, Joanita Kigozi³, Maria Sarah Nabaggala³, Vivian
8 Nakate³, Emmanuel Nkurunziza³, Daniel F. Stowell¹, Richard Walwema³, Apollo Olowo³,
9 Mohamed F. Jalloh¹

10
11 **Affiliations**

12 ¹Center for Global Health, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia,
13 USA.

14 ²National Center for Immunization and Respiratory Diseases, U.S. Centers for Disease Control
15 and Prevention, Atlanta, Georgia, USA.

16 ³Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala,
17 Uganda.

18 ⁴Uganda Ministry of Health.

19 ⁵Institute for Global Health Sciences, University of California San Francisco, California, USA

20

21

22

23

24 **Abstract**

25 **Background**

26 Uganda used Ebola vaccines as part of its preparedness and response during the 2018-2020 10th
27 Ebola virus disease (EVD) outbreak in neighboring Democratic Republic of the Congo (DRC).
28 We evaluated the public's perceptions of Ebola vaccines and compared their confidence in health
29 services to treat Ebola versus malaria and tuberculosis as part of a survey on Ebola knowledge,
30 attitudes, and practices (KAP) conducted in March 2020.

31 **Methods**

32 A cross-sectional household survey was implemented in six districts in Uganda using multi-stage
33 cluster sampling to randomly select participants. The districts were purposively selected from
34 districts classified by the government as at high- or low-risk for an EVD outbreak. We describe
35 perceptions of Ebola vaccines and confidence in health services to treat Ebola, tuberculosis, and
36 malaria. Modified Poisson regression modeling was used to identify the demographic correlates
37 of these outcomes.

38 **Results**

39 Among 3,485 respondents, 18% were aware of Ebola vaccines. Of those, 92% agreed that the
40 vaccines were needed to prevent Ebola. Participants aged 15-24 years were 4% more likely to
41 perceive such need compared to those 60 years and older (adjusted prevalence ratio [aPR] 1.04,
42 95% confidence interval [CI] 1.0-1.08). The perceived need was 5% lower among participants
43 with at least some secondary education compared to uneducated participants (aPR 0.95; 0.92-
44 0.99). Overall, 81% of those aware of the vaccines believed that everyone or most people in
45 their community would get vaccinated if offered, and 94% said they would likely get vaccinated

46 if offered. Confidence in health services to treat Ebola was lower compared to treating malaria or
47 tuberculosis (55% versus 93% and 77%, respectively). However, participants from the EVD
48 high-risk districts were 22% more likely to be confident in health services to treat Ebola
49 compared to those in low-risk districts (aPR: 1.22; 95% CI: 1.08, 1.38).

50 **Conclusion**

51 Our findings suggest that intent to take an Ebola vaccine during an outbreak was strong, but
52 more work needs to be done to increase public awareness of these vaccines. The public's high
53 confidence in health services to treat other health threats, such as malaria and tuberculosis, offer
54 building blocks for strengthening their confidence in health services to treat EVD in the event of
55 an outbreak.

56

57 **Introduction**

58 Outbreaks of Ebola virus disease (EVD) are complex and require a comprehensive package of
59 interventions. These include case management, infection prevention, and control, surveillance
60 and contact tracing, safe and dignified burials, and risk communication and community
61 engagement (RCCE) [1]. Additionally, the WHO 2018 Strategic Advisory Group of Experts
62 (SAGE) on Immunization recommended rVSV-ZEBOV-GP (Merck) vaccine against EVD as a
63 safe and effective prevention and response tool in EVD outbreaks caused by Zaire ebolavirus [2].

64

65 The 10th EVD outbreak in DRC was the second largest ever after the 2014–2016 West Africa
66 epidemic and was the deadliest in DRC history. It lasted nearly 2 years and resulted in over 3470
67 confirmed cases, with a case fatality rate of 66% [3]. In 2018, Uganda became the first country to
68 use Ebola vaccines as part of preparedness efforts in response to the outbreak in DRC. The

69 Uganda Ministry of Health (MOH), with support from the World Health Organization (WHO)
70 and other partners, offered the single dose Ebola vaccine, rVSV-ZEBOV, manufactured by
71 Merck, on a compassionate use basis to healthcare and frontline response workers in Ugandan
72 health facilities bordering DRC. At the time of implementation, the unlicensed Merck product
73 was the only vaccine approved for use in an outbreak and for disease prevention among frontline
74 health workers at high risk of exposure. From November 2018 through April 2019, 4419
75 healthcare workers were vaccinated in 13 high-risk districts. [4] In June 2019, three imported
76 cases of Ebola in Kasese District, Uganda, were confirmed in a family traveling from DRC. In
77 response, the MOH and WHO offered the Merck Ebola vaccine using a ring vaccination
78 approach to contacts, including both community members and healthcare workers. In total, 114
79 contacts were identified of whom 74 were vaccinated [5]. In August 2019, another imported case
80 of EVD was confirmed in Kasese District, and vaccination activities were implemented.
81 However, neither instance of EVD importation resulted in additional spread of the virus in
82 Uganda.

83
84 To increase vaccine acceptance and help contain and end outbreaks, community engagement
85 strategies used during Ebola preparedness and response efforts must build the public's
86 confidence in Ebola vaccines by creating awareness of EVD vaccines and promoting their need,
87 benefits, and safety [6]. Public perceptions about Ebola vaccines have been studied in various
88 settings, and results have consistently shown high acceptability, perceived need, and intention to
89 accept Ebola vaccines [7–11]. Notably, most existing evidence on the public perception of Ebola
90 vaccines has been collected in countries involved in the West African Ebola virus epidemic, and
91 some studies have taken place during ongoing EVD outbreaks [7,10]. Perceptions about Ebola

92 vaccines may differ in settings such as Uganda where outbreaks have historically been less
93 widespread and a smaller proportion of the population may have personal experiences related to
94 EVD. In Guinea, for example, intention to accept an Ebola vaccine towards the end of the 2014-
95 2016 West African Ebola virus epidemic was significantly higher among individuals who were
96 aware of new Ebola transmissions in their community and/or knew someone affected by Ebola
97 [10].

98
99 Vaccine confidence is defined as trust in (i) the effectiveness and safety of vaccines, (ii) the
100 system that delivers them, including the reliability and competence of the health services and
101 health professionals, and (iii) the motivations of policy-makers who decide on the need of
102 vaccines [12]. In addition to vaccine confidence, vaccine perceptions and uptake are associated
103 with risk perception of disease, structural and psychological constraints (e.g. vaccine access and
104 convenience), individual cost-benefit calculations, social norms, and collective responsibility to
105 protect others [13,14]. Confidence in health systems and the services they offer also influence
106 perceptions about vaccines, and vaccine confidence is correlated with confidence in the health
107 system [15]. Interventions that leverage trust in healthcare systems (e.g. vaccination
108 recommendations from trusted providers) are among the most effective ways to increase vaccine
109 uptake [14]. Understanding vaccine confidence and trust in health services is thus a key part of
110 building successful community engagement strategies aimed at strengthening Ebola
111 preparedness.

112
113 EVD vaccines are a pillar of EVD prevention and response, but the limited supply of vaccines,
114 and therefore access to vaccines precludes their widespread use. Community engagement

115 strategies must therefore build trust in vaccines despite the ineligibility of most individuals for
116 vaccination during an outbreak. To guide future RCCE strategies in EVD outbreak preparedness
117 and response in Uganda, we evaluated the public's perceptions of Ebola vaccines and compared
118 their confidence in health services to treat Ebola versus malaria and tuberculosis.

119

120 **Materials and Methods**

121 We conducted a cross-sectional household survey among persons 15 years of age and older in six
122 districts in Uganda following the 2018-2020 10th EVD outbreak in neighboring DRC. Our
123 purposive selection of these six districts was informed by the Uganda government's
124 classification of districts into varying risk profiles for a potential cross border spillover EVD
125 outbreak from the DRC [4]. We selected four high-risk districts (Arua, Kasese, Kisoro, and
126 Greater Kampala) and two low-risk districts (Busia and Lamwo) for the survey, the methods of
127 which have been elaborated elsewhere [16]. To summarize, we used multistage sampling to
128 select geographic clusters, households, and individuals to interview. The 2016 Uganda National
129 Population Housing Census served as the sampling frame for the random selection of clusters
130 with probability proportional to size within each district [17]. Sample size was calculated to
131 provide district-level estimates of the public's knowledge, beliefs, attitudes and practices related
132 to EVD risks. After adjusting for an expected 25% level of non-responsiveness, 640 eligible
133 individuals from 20 clusters were approached for consent in each district. Trained interviewers
134 administered questionnaires to participants in local languages (see Supplemental Materials).

135

136 **Measures**

137 Our main outcomes were perceptions of Ebola vaccines and confidence in health services to treat
138 Ebola, malaria and tuberculosis among respondents who reported being aware of Ebola vaccines.
139 Awareness was assessed by asking participants if they had ever heard about an Ebola vaccine
140 before their interview.

141

142 **Perceptions of Ebola vaccines**

143 We used three variables to measure perceptions of Ebola vaccines: (1) perceived need for Ebola
144 vaccines to prevent EVD during an EVD outbreak, (2) perceived acceptability of Ebola vaccines
145 by others if offered in the event of an outbreak, and (3) intention to accept the vaccine for oneself
146 if offered in the event of an outbreak. These variables were adapted because they showed
147 acceptable scale reliability and criterion validity in Sierra Leone during the 2014-2015 Ebola
148 epidemic [7]. Questions on perceptions of Ebola vaccines were only asked to individuals who
149 reported having heard of the vaccines prior to their interview. Perceived need for Ebola vaccines
150 was measured by asking participants if they agree, somewhat agree, or disagree with the
151 statement that “If Uganda started having cases of Ebola, an Ebola vaccine is needed to help
152 prevent the spread of the disease in the country.” We generated a binary variable to group
153 participants who said they agree or somewhat agree (coded 1) versus disagree (coded 0). To
154 measure perceptions of acceptability by others in the community, participants were asked “If
155 there is an Ebola outbreak in your district, how many people in your community do you think
156 would agree to take an Ebola vaccine if they were offered it?”. A binary variable was created to
157 group participants who said everyone or most people would agree (coded 1) or versus some or no
158 one would agree (coded 0). Intention to accept Ebola vaccines was measured by asking
159 participants “If there is an Ebola outbreak in your district, how likely would you be to take an

160 Ebola vaccine for yourself if you were offered it?”. We generated a binary variable where
161 individuals who were very likely or somewhat likely to take an Ebola vaccine were grouped
162 separately (coded 1) from individuals who were not very likely or not at all likely (coded 0).

163

164 **Confidence in health services**

165 Confidence in the health care system was measured by asking participants to rate their
166 confidence in the system to care for Ebola, tuberculosis (TB), and malaria. Questions on
167 confidence in the health care system were asked to all survey participants. Participants had the
168 option to rate their confidence as “not at all confident,” “somewhat confident,” and “very
169 confident” in the district health services to treat each of the three diseases. We generated separate
170 binary categorical variables for each disease, and individuals who were very or somewhat
171 confident were categorized as having high confidence (coded 1) while individuals who were not
172 at all confident were categorized as having low confidence (coded 0).

173

174 **Statistical analysis**

175 All analyses were conducted in STATA 16 (College Station, Texas) and weighted to account for
176 the complex survey design. District-specific post-stratification weights were used to pool data
177 from all districts included in this analysis. We conducted bivariable analyses by comparing
178 frequencies, proportions, and 95% confidence intervals (CI) of proportions of our outcomes of
179 interest across sociodemographic characteristics, and residence in a high-risk versus low-risk
180 district.

181

182 We then used multivariable models to explore associations between sociodemographic
183 characteristics and our main outcomes. The following sociodemographic covariates were
184 included in all models: sex (females *vs* male), head of household status (no *vs* yes), age category
185 (60+ *vs* 45-59, 35-44, 25-34, 15-24 years), religion (Christian *vs* Muslim), education (no
186 education *vs* some primary *or* at least some secondary) residential setting (urban *vs* rural), district
187 (low Ebola risk *vs* high Ebola risk).

188
189 Models for Ebola vaccine perceptions were restricted to individuals who were aware of Ebola
190 and Ebola vaccines. Separate multivariable models were used to examine the associations of
191 sociodemographic covariates with: (1) the perceived need for EVD vaccines, (2) perceived
192 community acceptability of EVD vaccines, and (3) intention to accept EVD vaccines. Separate
193 multivariable models were used to examine the associations of sociodemographic covariates
194 with: (1) confidence in health services to treat EVD, (2) confidence in health services to treat
195 malaria, and (3) confidence in health services to treat tuberculosis. Models excluded individuals
196 who had never heard of a respective health outcome (EVD, malaria, tuberculosis) prior to their
197 interview.

198
199 We fit the models using modified Poisson regression with robust variance estimation to calculate
200 the adjusted prevalence ratios and corresponding 95% confidence intervals (CI). We used
201 variance inflation factor (VIF) to examine multicollinearity in each of the multivariable models
202 [18]. No evidence of multicollinearity was detected in any of the models (mean VIF values were
203 < 4 for each of the six models). In all models, a two-sided P value < 0.05 was considered

204 statistically significant. Data missingness was < 2%, therefore we did not perform sensitivity
205 analysis for missing data.

206

207 **Ethical considerations**

208 Ethical approval was obtained from the Uganda Virus Research Institute Research Ethics
209 Committee (UVRI REC GC/127/19/11/756) and the survey was registered with the Uganda
210 National Council for Science and Technology (HS531ES). The U.S. Centers for Disease
211 Control and Prevention approved the survey as a non-research public health activity. All
212 respondents provided individual written (or thumb-printed if illiterate) informed consent prior to
213 the interview. For respondents aged 15-17 years, consent was obtained from a parent, guardian,
214 or household head, as well as assent from the respondent.

215

216 **Results**

217 The study population included 3,485 participants (Table 1). Across all six districts, 60% of
218 participants were female, 78% were aged 25 years or older, and 69% lived in rural communities.

219

220 **Table 1.** Sociodemographic characteristics of participants and district-level Ebola risk profile,
221 Uganda, March 2020

Characteristic	Overall (N=3,485)	District Ebola risk	
		Low-risk district (N=1,227)	High-risk district (N=2,258)
Sex			
Female	2,106 (60.4)	693 (56.5)	1,413 (62.6)

Male	1,379 (39.6)	534 (43.5)	845 (37.4)
Head of household			
No	1,716 (49.2)	611 (49.8)	1,105 (48.9)
Yes	1,769 (50.8)	616 (50.2)	1,153 (51.1)
Age (years)[¶]			
15-24	761 (21.8)	284 (23.2)	477 (21.1)
25-34	878 (25.2)	286 (23.3)	592 (26.2)
35-44	715 (20.5)	244 (19.9)	471 (20.9)
45-59	686 (19.7)	242 (19.7)	444 (19.7)
60 or older	445 (12.8)	171 (13.9)	274 (12.1)
Religion[‡]			
Christian	3,184 (91.6)	1,116 (91.3)	2,068 (91.8)
Muslim	293 (8.4)	107 (8.8)	186 (8.3)
Education[‡]			
No formal education	640 (18.4)	201 (16.4)	439 (19.5)
Some primary	1,747 (50.2)	650 (53.1)	1,097 (48.6)
Some secondary or higher	1,093 (31.4)	373 (30.5)	720 (31.9)
Residential setting[¶]			
Urban	1,089 (31.3)	270 (22.0)	819 (36.3)
Rural	2,396 (68.8)	957 (78.0)	1,439 (63.7)

222 ‡ Missing values: religion (n=8)

223 ¶ Age categorized and residential setting classified as per the 2016 Uganda Demographic and Health Survey
224 provided by the Uganda Bureau of Statistics

225

226 Overall, almost all individuals (96%) had heard of Ebola prior to the interview. Among the
227 individuals that had heard of Ebola (N=3352), only 627 (18%) had heard of Ebola vaccines prior
228 to their interview. Among 627 participants who had heard of EVD vaccines, 25 said they had
229 been offered the Ebola vaccine, of whom 18 (72%) were vaccinated, 5 (20%) declined
230 vaccination, and 2 (8%) declined to answer or had missing values.

231 Among 627 participants who had heard of Ebola vaccines, 88% (95% CI: 83, 92) agreed and 4% (95% CI: 2.5, 6.1) somewhat agreed
 232 that a vaccine is needed to help prevent the spread of EVD in the country during an outbreak (Table 2).

233 **Table 2.** Perceptions about Ebola vaccines and health services by district-level Ebola risk profile, Uganda, March 2020

234

	All districts		Low-risk districts		High-risk districts	
	N	% (95% CI)	N	% (95% CI)	N	% (95% CI)
EBOLA VACCINE CONFIDENCE						
Importance If Uganda started having cases of Ebola, an Ebola vaccine is needed to help prevent the spread of the disease in the country[†]						
Agree	609	88.2 (83.4, 91.9)	109	87.5 (76.5, 93.8)	500	88.4 (82.7, 92.4)
Somewhat agree		4.0 (2.5, 6.1)		11.2 (5.1, 22.7)		2.5 (1.5, 4.2)
Disagree		7.8 (4.5, 13.2)		1.3 (0.2, 8.1)		9.1 (5.1, 15.6)
Acceptability: If there is an Ebola outbreak in your district, how many people in your community do you think would agree to take an Ebola vaccine if they were offered it?^{†¶}						
No one	611	0.5 (0.1, 3.1)	113	0.0	498	0.7 (0.1, 3.6)
Some people		18.4 (15.6, 21.5)		18.0 (10.2, 29.8)		18.5 (15.7, 21.5)
Most people		49.8 (44.9, 54.7)		56.2 (43.9, 67.7)		48.6 (43.3, 53.9)
Everyone		31.2 (26.9, 35.9)		25.8 (16.0, 38.8)		32.3 (27.6, 37.3)
Intention: If there is an Ebola outbreak in your district, how likely would you be to take an Ebola vaccine for yourself if you were offered it?^{†¶¶}						
Very likely to take it	617	94.0 (90.4, 96.3)	114	93.5 (86.2, 97.0)	503	94.1 (89.8, 96.6)
Somewhat likely to take it		4.0 (2.5, 6.3)		4.0 (1.6, 9.7)		4.0 (2.4, 6.7)

Not very likely to take it		1.0 (0.3, 3.0)		1.7 (0.2, 11.8)		0.8 (0.2, 3.3)
Not at all likely to take it		1.0 (0.3, 3.5)		0.8 (0.1, 6.2)		1.1 (0.3, 4.2)
HEALTH SERVICES TO TREAT EBOLA, MALARIA, AND TUBERCULOSIS						
Total respondents	3,485		1,227		2,258	
EVD: How confident are you in the health services in your district to treat Ebola?†						
Not at all confident	3,302	45.3 (41.8, 48.8)	1,109	51.7 (46.6, 56.8)	2,193	44.0 (40.0, 48.1)
Somewhat confident		26.1 (23.6, 28.7)		32.2 (27.8, 36.9)		24.9 (22.1, 27.9)
Very confident		28.6 (25.0, 32.5)		16.1 (12.6, 20.3)		31.1 (26.8, 35.7)
TB: How confident are you in the health services in your district to treat tuberculosis (TB/dry cough)?‡						
Not at all confident	3,330	23.0 (20.5, 25.6)	1,183	16.2 (12.8, 20.4)	2,147	24.3 (21.4, 27.4)
Somewhat confident		33.4 (30.4, 36.5)		52.9 (49.1, 56.7)		29.5 (26.1, 33.2)
Very confident		43.6 (40.0, 47.4)		30.9 (27.0, 35.1)		46.2 (41.8, 50.6)
Malaria: How confident are you in the health services in your district to treat malaria?‡‡‡						
Not at all confident	3,460	7.0 (4.3, 11.3)	1,216	6.4 (4.4, 9.2)	2,244	7.1 (4.0, 12.4)
Somewhat confident		27.9 (25.3, 30.7)		52.0 (46.4, 57.5)		23.2 (20.2, 26.4)
Very confident		65.1 (60.7, 69.2)		41.7 (35.9, 47.7)		69.7 (64.5, 74.4)

235 N denotes number of respondents (un-weighted), % percentage estimates and CI confidence interval both weighted for survey sampling

236 § Design-based F-statistic p values for comparing high-risk versus low-risk districts.

237 † Analysis on confidence on Ebola vaccine included only those who had ever heard about Ebola vaccine prior to the interview, overall=621 (Low-risk districts
238 n=115, High-risk districts n=506)

239 ¶ Analysis excluded: 11 responded don't know

¶¶ Analysis excluded: 10 responded don't know

¶¶¶ Analysis excluded: 3 responded don't know, and 1 missing response

‡ Of the total respondents in the survey (N=3,485), this analysis excluded: n=133 responded never heard of Ebola, n=50 declined to respond.

‡‡ Analysis excluded: those responded never heard of TB (n=116), declined to respond (n=39).

‡‡‡ Analysis excluded: those responded never heard of malaria (n=12), declined to respond (n=13).

Participants aged 15-24 years were 4% more likely to perceive a need for vaccines during an outbreak compared to those 60 years and older (aPR 1.04; 95% CI 1.00-1.08) (Table 3).

Table 3. Perception about Ebola vaccine by sociodemographic characteristics, Uganda, March 2020

Characteristic	Perceived that Ebola vaccines are needed to prevent Ebola †			Believed all or most people would accept Ebola vaccine if offered†††			Intended to accept Ebola vaccine if offered††		
	N=609			n=610			N=617		
	n	%	aPR (95% CI)	n	%	aPR (95% CI)	n	%	aPR (95% CI)
Sex									
Female	332	90.1	Reference	331	79.1	Reference	337	98.7	Reference
Male	277	96.4	0.98 (0.95, 1.00)	280	84.8	1.01 (0.92, 1.10)	280	96.6	0.99 (0.96, 1.01)
Head of household									
No	256	85.3	Reference	258	83.7	Reference	260	98.3	Reference
Yes	353	97.2	1.01 (0.98, 1.05)	353	79.2	1.08 (0.97, 1.20)	357	97.8	1.00 (0.97, 1.03)
Age (years)[¶]									
15-24	106	100	1.04* (1.00, 1.08)	107	82.7	1.02 (0.89, 1.18)	107	97.0	1.01 (0.96, 1.05)
25-34	161	80.6	0.99 (0.96, 1.02)	163	64.7	0.91 (0.79, 1.05)	165	97.9	0.99 (0.95, 1.03)
35-44	134	98.6	1.00 (0.96, 1.04)	131	92.3	1.05 (0.94, 1.18)	133	99.0	1.00 (0.97, 1.04)
45-59	139	96.4	0.99 (0.95, 1.03)	140	91.2	1.05 (0.95, 1.17)	142	97.3	1.01 (0.97, 1.04)
60 or older	69	98.9	Reference	70	90.7	Reference	70	98.8	Reference
Religion									
Christian	553	95.3	Reference	553	79.4	Reference	559	97.8	Reference
Muslim	56	75.8	0.98 (0.92, 1.05)	58	89.7	1.06 (0.93, 1.21)	58	99.0	0.99 (0.93, 1.05)
Education									
No formal education	92	100	Reference	89	94.7	Reference	91	100.0	Reference
Some primary	275	91.3	0.98 (0.96, 1.00)	280	82.6	0.96 (0.86, 1.07)	282	99.6	0.99 (0.98, 1.01)
Some secondary or higher	241	91.6	0.95* (0.92, 0.99)	241	77.0	0.95 (0.84, 1.07)	243	96.1	0.97 (0.93, 1.00)
Residential setting[¶]									
Urban	206	88.5	Reference	205	78.7	Reference	206	97.8	Reference
Rural	403	98.5	1.01 (0.98, 1.06)	406	85.1	1.06 (0.97, 1.17)	411	98.3	1.01 (0.98, 1.05)
District									
Low Ebola risk	109	98.7	Reference	113	82.0	Reference	114	97.4	Reference
High Ebola risk	500	90.9	0.98 (0.95, 1.00)	498	80.9	1.07 (0.95, 1.18)	503	98.1	0.99 (0.96, 1.03)

N denotes number of respondents (un-weighted), % row percentage estimates and CI confidence interval both weighted for survey sampling

* p< 0.05; **p<0.01; Design-based F-statistic p values comparing prevalence across categories of a specific characteristic.

† Analysis performed on N=609 of 621 respondents who reported that they were aware of Ebola vaccine: n=1 declined to respond and n=11 responded don't know.

†† Analysis performed on N=617 of 621 respondents who reported that they were aware of Ebola vaccine: n=1 declined to respond and n=3 responded don't know.

††† Analysis performed on N=617 of 621 respondents who reported that they were aware of Ebola vaccine: n=10 responded don't know.

‡ Missing values: education (n=1)

¶ Age categorized and residential setting classified as per the 2016 Uganda Demographic and Health Survey provided by the Uganda Bureau of Statistics

The perceived need was 5% lower among participants with at least some secondary education compared to uneducated participants (aPR 0.95; 0.92-0.99). If an Ebola vaccine was offered during an outbreak in their district, 94% (95% CI: 90, 96) were likely to take it and most individuals believed everyone (31%; 95% CI: 27, 36) or most people (50%; 95% CI: 45, 55) in their district would agree to take the vaccine. Perceptions about vaccines did not vary by high versus low-risk districts. Over 75% of participants stated that they had no concerns about the Ebola vaccine. Among those that expressed a concern, fear of vaccine side effects was most frequently reported (9%; 95% CI: 7, 11; Fig 1).

Figure 1. Percent distribution of reported concerns regarding Ebola vaccines among individuals aware of the vaccine at the time of the interview (N=620)

Almost everyone in our survey was aware of EVD, TB and malaria with little variability by sociodemographic characteristics (S1 Table). Awareness about EVD prior to the interview was higher in high-risk versus low-risk districts (99% vs 89%) but did not vary across other sociodemographic characteristics (S1 Table). Strong confidence in health services to treat different diseases was highest for malaria (65%), followed by TB (44%) and EVD (29%) (Table 2).

We identified no major differences in confidence in health services to treat EVD by sociodemographic variables in multivariable analyses (Table 4).

Table 4. Confidence in health services to treat Ebola, TB and malaria, by sociodemographic characteristics, Uganda, March 2020

Characteristic	Confident in health services to treat Ebola [†] N=3,302			Confident in health services to treat TB ^{††} N= 3,195			Confident in health services to treat Malaria ^{†††} N= 3,460		
	N	%	aPR (95% CI)	N	%	aPR (95% CI)	N	%	aPR (95% CI)
Sex									
Female	1,997	54.5	Reference	2,017	75.7	0.98 (0.94, 1.02)	2,090	93.0	Reference
Male	1,305	55.1	0.96 (0.89, 1.04)	1,313	79.9		1,370	93.1	0.99 (0.97, 1.01)
Head of household									
No	1,615	52.6	Reference	1,636	74.4	Reference	1,702	93.2	Reference
Yes	1,687	56.8	1.04 (0.96, 1.14)	1,694	79.7	1.00 (0.96, 1.05)	1,758	92.7	0.99 (0.98, 1.01)
Age (years)									
15-24	710	56.0	1.05 (0.92, 1.20)	719	76.2	0.97 (0.90, 1.04)	753	92.3	0.99 (0.97, 1.03)
25-34	844	50.6	1.03 (0.91, 1.16)	839	71.1	0.97 (0.92, 1.02)	870	94.2	1.00 (0.97, 1.03)
35-44	680	53.9	1.01 (0.90, 1.14)	686	73.8	0.96 (0.91, 1.01)	713	92.7	0.99 (0.96, 1.03)
45-59	661	58.2	1.03 (0.93, 1.14)	652	84.4	1.00 (0.95, 1.06)	682	91.2	0.98 (0.95, 1.02)
60 or older	407	58.8	Reference	434	87.9	Reference	442	94.9	Reference
Religion									
Christian ^A	2,972	55.7	Reference	2,989	79.0	Reference	3,108	93.5	Reference
Muslim	328	49.4	0.94 (0.84, 1.06)	339	66.3	0.97 (0.91, 1.03)	350	90.2	0.96 (0.93, 1.00)
Education									
No formal education	612	61.9	Reference	617	84.5	Reference	637	92.1	Reference
Some primary	1,642	54.1	0.99 (0.91, 1.08)	1,668	74.2	0.98 (0.94, 1.03)	1,732	92.6	0.99 (0.97, 1.02)

Some secondary or higher	1,043	53.2	0.99 (0.89, 1.09)	1,040	78.1	1.02 (0.97, 1.07)	1,086	93.6	1.01 (0.98, 1.04)
Residential setting									
Urban	1,043	52.2	Reference	1,048	72.9	Reference	1,080	92.5	Reference
Rural	2,259	58.6	1.09 (0.98, 1.22)	2,282	83.5	1.06 (0.99, 1.14)	2,380	93.8	1.02 (0.99, 1.05)
District									
Low Ebola risk	1,109	48.2	Reference	1,183	83.8	Reference	1,216	93.6	Reference
High Ebola risk	2,193	56.0	1.22** (1.08, 1.38)	2,147	75.7	0.99 (0.93, 1.05)	2,244	92.9	0.99 (0.97, 1.03)

N denotes number of respondents (un-weighted), % percentage estimates and CI confidence interval both weighted for survey sampling

* p< 0.05; **p<0.01; Design-based F-statistic p values comparing prevalence across categories of a specific characteristic.

† Of the total respondents in the survey (N=3,485), this analysis excluded: n=133 responded never heard of Ebola, n=50 declined to respond.

†† Analysis excluded: those responded never heard of TB (n=116), declined to respond (n=39).

††† Analysis excluded: those responded never heard of malaria (n=12), declined to respond (n=13).

‡ Missing values: religion (n=2), education (n=5)

¶ Age categorized and residential setting classified as per the 2016 Uganda Demographic and Health Survey provided by the Uganda Bureau of Statistics

However, individuals living in high-risk districts reported more confidence in health services to treat EVD compared to individuals in low-risk districts (aPR 1.22; 95% CI: 1.08, 1.38) (Table 4). High and low-risk districts had similar confidence in health services to treat TB (aPR: 0.99; 95% CI: 0.93, 1.05) and malaria (aPR: 0.99; 95% CI: 0.97, 1.03).

Discussion

Among survey respondents who had heard of Ebola vaccines, we found high perceived need for Ebola vaccines and high intent to take an Ebola vaccine in Uganda during a protracted EVD outbreak in neighboring DRC. This finding suggests that messaging on the availability, safety, and effectiveness of Ebola vaccines is a vital part of Ebola preparedness and outbreak response efforts.

Additionally, nearly everyone that was aware of Ebola vaccines intended to accept the vaccine if offered during an outbreak and believed that the vaccine would help prevent the spread of EVD in event of an outbreak. Approximately 8 out of every 10 participants that were aware of the vaccine perceived that all or most people in their community would accept the vaccine if offered during an outbreak. Less than 20% of survey participants had heard of Ebola vaccines prior to their interview, and it is possible that those who were aware of the vaccine were also more likely to have positive attitudes toward the vaccine compared to those who were not. Risk communication materials for the public in Uganda included only basic information about the availability of vaccines to prevent EVD transmission. More detailed information about the importance, efficacy and safety of vaccines was targeted towards health care and frontline workers who were eligible for vaccination and was not widespread in communities. Awareness

of Ebola vaccines was highest (42%) in the outbreak district, Kasese, and lowest in the low-risk districts, Busia (8%) and Lamwo (12%), providing some evidence that vaccine administration was associated with higher community awareness of Ebola vaccines.

Nearly half of all respondents that were aware of Ebola prior to their interview did not have confidence in health services to treat Ebola in their district. In contrast to malaria and tuberculosis treatment, EVD treatment occurs in Ebola Treatment Units (ETUs) that are specifically set up only during EVD outbreaks. The survey was not conducted during an EVD outbreak, therefore the low confidence in routine health services to treat Ebola may reflect lack of ETUs at the time of the survey. Greater confidence in health services to treat EVD in the high-risk districts may have been influenced by the increased investments in the overall health systems in these high-risk districts as part of outbreak preparedness and response. For example, during the 2014 EVD outbreak in Sierra Leone, districts with active EVD outbreaks had intensified social mobilization, greater infrastructure and response capacity (e.g. additional ambulances), and district response centers [19]. Our finding of higher confidence in health services to treat Ebola in high-risk districts is consistent with results from Sierra Leone where respondents who lived in districts with active Ebola outbreaks in 2015 expressed more confidence in the health care system to treat Ebola and provide other health services compared to nonactive districts [19].

Lower confidence in health services to treat EVD compared to malaria and tuberculosis may be reflective of the higher current and historical prevalence of these diseases in Uganda and participants' more recent experiences with health systems for these conditions. Confidence in

health services to treat Ebola in Sierra Leone in 2015 was substantially higher compared to our study population (93% vs 55%) [19], but our ability to directly compare our results with settings that had active Ebola transmission at the time of data collection is limited. This suggests that, if an Ebola outbreak originates or spills into low-risk districts, RCCE to strengthen public confidence in Ebola treatment services needs to be rapidly scaled up given the current lower baseline confidence compared to the high-risk districts. RCCE messages should describe ETUs and the specific treatment services they provide, emphasizing how available services can significantly improve chances of survival if given early.

Vaccine confidence and perceptions are shaped by many factors, including confidence in the health systems that deliver them. While half of the respondents did not have confidence in health services to treat Ebola in their district, it is possible that confidence in other health services bolstered trust in vaccines and vaccinators. In the event of an outbreak, intensified efforts may be needed to strengthen confidence in health services to treat Ebola in order to effectively detect, treat, and isolate EVD cases. While consistent community engagement activities before, during, and after outbreaks are needed to build long-term trust in health systems, our findings suggest vaccination efforts can be a successful pillar of EVD prevention and control even in settings with low trust in health services to treat health outcomes. For example, during the recent 2022 outbreak of Sudan ebolavirus [20] in the previously low-risk district of Mubende, Ugandan health officials rapidly disseminated RCCE messages to explain the purpose of the ETUs and to build community trust. A ring vaccination protocol (Solidarity-Tokomeza Ebola) was developed and locally approved to test three candidate vaccines. However, because Sudan ebolavirus

vaccines were only available through a clinical trial, in contrast to the availability of licensed vaccines for Zaire ebolavirus, RCCE for Sudan ebolavirus vaccines was very limited.

Limitations

Our findings are susceptible to social desirability bias, and individuals in high-risk districts where RCCE messages about Ebola were more widely disseminated may have been more likely to provide positive views about the vaccine and health services [16]. Nevertheless, our findings of high confidence for Ebola vaccines in high-risk areas for EVD outbreaks are consistent with population-based studies conducted in South Sudan, Guinea, and Sierra Leone [7,10]. We were unable to examine predictors of vaccine confidence in our study population given the low proportion of respondents that were aware of vaccines and low heterogeneity in perceived need, perceived acceptability, and vaccination intentions. KAP studies of Ebola vaccine confidence should be a standard part of EVD preparedness activities to inform vaccine-specific communications and to identify groups with low confidence that require additional focus. We did not comprehensively measure vaccine confidence and may not have captured important variability in other domains of confidence, such as the belief that vaccines work, trust in vaccine safety, and perceived benefits of vaccination. Early and ongoing information sharing about the importance, effectiveness and safety of EVD vaccines will not only build vaccine confidence but will help establish early support for the vaccination teams and vaccination activities should an outbreak occur.

Conclusion

Our findings suggest that public confidence in Ebola vaccines was strong once people had received information about them, which may yield high vaccination uptake in the event of an EVD outbreak. Ongoing risk information, education, and communication about Ebola and community engagement (RCCE) that highlight the critical roles of communities in supporting care and immunization efforts during periods without outbreaks may be a critical strategy for strengthening Ebola emergency preparedness and response in the event of an outbreak.

Funding statement

The U.S. Centers for Disease Control and Prevention funded the Infectious Disease Institute in Kampala to implement the survey (Cooperative Agreement # NU2GGH001744)

Disclaimer

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the U.S. Centers for Disease Control and Prevention.

Competing interests

None declared.

Acknowledgements

We thank the study participants, without whom this work would not be possible.

References


- [1] Ebola virus disease n.d. <https://www.who.int/news-room/fact-sheets/detail/ebola-virus-disease> (accessed March 26, 2022).
- [2] World Health Organization. Meeting of the Strategic Advisory Group of Experts on Immunization, October 2018: conclusions and recommendations. 2018.
- [3] History of Ebola Virus Disease (EVD) Outbreaks | History | Ebola (Ebola Virus Disease) | CDC 2022. <https://www.cdc.gov/vhf/ebola/history/chronology.html> (accessed January 4, 2023).
- [4] Aceng JR, Ario AR, Muruta AN, Makumbi I, Nanyunja M, Komakech I, et al. Uganda's experience in Ebola virus disease outbreak preparedness, 2018–2019. *Global Health* 2020;16:24. <https://doi.org/10.1186/s12992-020-00548-5>.
- [5] Republic of Uganda - Ministry of Health. Ebola Virus Disease in Uganda. 2019.
- [6] Lessons learned from engaging communities for Ebola vaccine trials in Sierra Leone: reciprocity, relatability, relationships and respect (the four R's) | BMC Public Health | Full Text n.d. <https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-019-7978-4> (accessed August 19, 2022).
- [7] Ebola vaccine? Family first! Evidence from using a brief measure on Ebola vaccine demand in a national household survey during the outbreak in Sierra Leone - PubMed n.d. <https://pubmed.ncbi.nlm.nih.gov/32291102/> (accessed March 28, 2022).
- [8] Huo X, Shi G, Li X, Lai X, Deng L, Xu F, et al. Knowledge and attitudes about Ebola vaccine among the general population in Sierra Leone. *Vaccine* 2016;34:1767–72. <https://doi.org/10.1016/j.vaccine.2016.02.046>.

- [9] Jendrossek M, Edmunds WJ, Rohan H, Clifford S, Mooney TA, Eggo RM. Health care worker vaccination against Ebola: Vaccine acceptance and employment duration in Sierra Leone. *Vaccine* 2019;37:1101–8. <https://doi.org/10.1016/j.vaccine.2018.12.060>.
- [10] Irwin KL, Jalloh MF, Corker J, Alpha Mahmoud B, Robinson SJ, Li W, et al. Attitudes about vaccines to prevent Ebola virus disease in Guinea at the end of a large Ebola epidemic: Results of a national household survey. *Vaccine* 2017;35:6915–23. <https://doi.org/10.1016/j.vaccine.2017.06.026>.
- [11] Ughasoro MD, Esangbedo DO, Tagbo BN, Mejeha IC. Acceptability and Willingness-to-Pay for a Hypothetical Ebola Virus Vaccine in Nigeria. *PLoS Negl Trop Dis* 2015;9:e0003838. <https://doi.org/10.1371/journal.pntd.0003838>.
- [12] MacDonald NE, SAGE Working Group on Vaccine Hesitancy. Vaccine hesitancy: Definition, scope and determinants. *Vaccine* 2015;33:4161–4. <https://doi.org/10.1016/j.vaccine.2015.04.036>.
- [13] Betsch C, Schmid P, Heinemeier D, Korn L, Holtmann C, Böhm R. Beyond confidence: Development of a measure assessing the 5C psychological antecedents of vaccination. *PLOS ONE* 2018;13:e0208601. <https://doi.org/10.1371/journal.pone.0208601>.
- [14] Brewer NT. What Works to Increase Vaccination Uptake. *Academic Pediatrics* 2021;21:S9–16. <https://doi.org/10.1016/j.acap.2021.01.017>.
- [15] Larson HJ, Schulz WS, Tucker JD, Smith DMD. Measuring Vaccine Confidence: Introducing a Global Vaccine Confidence Index. *PLoS Curr* 2015;7:ecurrents.outbreaks.ce0f6177bc97332602a8e3fe7d7f7cc4. <https://doi.org/10.1371/currents.outbreaks.ce0f6177bc97332602a8e3fe7d7f7cc4>.

- [16] Musaaazi J, Namageyo-Funa A, Carter VM, Carter RJ, Lamorde M, Apondi R, et al. Evaluation of Community Perceptions and Prevention Practices Related to Ebola Virus as Part of Outbreak Preparedness in Uganda, 2020. *Global Health: Science and Practice* 2022;10. <https://doi.org/10.9745/GHSP-D-21-00661>.
- [17] Uganda Bureau of Statistics 2016. The National Population and Housing Census 2014 – Main Report. Kampala, Uganda: n.d.
- [18] Regression with Stata Chapter 2 – Regression Diagnostics n.d. <https://stats.idre.ucla.edu/stata/webbooks/reg/chapter2/stata-webbooksregressionwith-statachapter-2-regression-diagnostics/> (accessed January 25, 2020).
- [19] Li W, Jalloh MF, Bunnell R, Aki-Sawyer Y, Conteh L, Sengeh P, et al. Public Confidence in the Health Care System 1 Year After the Start of the Ebola Virus Disease Outbreak — Sierra Leone, July 2015. *Morbidity and Mortality Weekly Report* 2016;65:538–42.
- [20] Ebola disease caused by Sudan ebolavirus – Uganda n.d. <https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON433> (accessed January 16, 2023).

S1 Table. Awareness of Ebola virus disease, tuberculosis, and malaria by sociodemographic characteristics, Uganda, March 2020

S2 Table. Perceptions about Ebola vaccines and confidence in health services by district-level Ebola risk profile, Uganda, March 2020



Figure